Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how DaVita HealthCare (DVA) and Avadel (AVDL) have performed compared to their sector so far this year.
DaVita's (DVA) robust segmental revenues drive its second-quarter performance.
DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.08 per share a year ago.
Improvement in RPT and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the second quarter.
In the latest trading session, DaVita HealthCare (DVA) closed at $136.47, marking a -1.93% move from the previous day.
As the second half of 2024 unfolds, the stock market continues to offer various investment opportunities ranging from large to small-cap equities.
The latest trading day saw DaVita HealthCare (DVA) settling at $139.96, representing a +1.46% change from its previous close.
DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.